Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center-Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.
Department of Gynaecology and Gynaecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
Int J Gynecol Cancer. 2018 Nov;28(9):1692-1698. doi: 10.1097/IGC.0000000000001361.
Poor survival of high-grade serous pelvic cancer is caused by a lack of effective screening measures. The detection of exfoliated cells from high-grade serous pelvic cancer, or precursor lesions, is a promising concept for earlier diagnosis. However, collecting those cells in the most efficient way while fulfilling all requirements for a screening approach is a challenge. We introduce a new catheter for uterine and tubal lavage (UtL) and the clinical evaluation of its performance.
METHODS/MATERIALS: In study I, the clinical feasibility of the UtL using the new catheter was examined in 93 patients admitted for gynecologic surgery under general anesthesia. In study II, the safety of the UtL procedure was assessed. The pain during and after the UtL performed under local anesthesia was rated on a visual analog scale by 22 healthy women.
In study I, the UtL was carried out successfully in 92 (98.9%) of 93 cases by 16 different gynecologists. It was rated as easy to perform in 84.8% of patients but as rather difficult in cancer patients (odds ratio, 5.559; 95% confidence interval, 1.434-21.546; P = 0.007). For benign conditions, dilatation before UtL was associated with menopause status (odds ratio, 4.929; 95% confidence interval, 1.439-16.884; P = 0.016). In study II, the pain during UtL was rated with a median visual analog scale score of 1.6. During a period of 4 weeks after UtL, none of the participants had to use medication or developed symptoms requiring medical attention. The UtL took 6.5 minutes on average. The amount of extracted DNA was above the lower limit for a sensitive, deep-sequencing mutation analysis in all cases.
Our studies demonstrate that the UtL, using the new catheter, is a safe, reliable, and well-tolerated procedure, which does not require elaborate training. Therefore, UtL fulfils all prerequisites to be used in a potential screening setting.
高级别浆液性盆腔癌的存活率低,是因为缺乏有效的筛查措施。脱落细胞的检测高级别浆液性盆腔癌,或前体病变,是一个有前途的概念,用于早期诊断。然而,以最有效的方式收集这些细胞,同时满足筛查方法的所有要求,是一个挑战。我们介绍了一种新的导管,用于子宫和输卵管灌洗(UtL),并对其性能进行了临床评估。
方法/材料:在研究 I 中,在全身麻醉下接受妇科手术的 93 名患者中检查了使用新导管的 UtL 的临床可行性。在研究 II 中,评估了 UtL 程序的安全性。22 名健康女性使用视觉模拟评分法对局部麻醉下进行的 UtL 过程中的疼痛和之后的疼痛进行了评分。
在研究 I 中,16 位不同的妇科医生成功地对 93 例中的 92 例(98.9%)进行了 UtL。它在 84.8%的患者中被评为易于实施,但在癌症患者中被评为相当困难(比值比,5.559;95%置信区间,1.434-21.546;P=0.007)。对于良性疾病,UtL 前的扩张与绝经状态有关(比值比,4.929;95%置信区间,1.439-16.884;P=0.016)。在研究 II 中,UtL 过程中的疼痛评分为中位数视觉模拟评分 1.6。在 UtL 后的 4 周内,没有参与者需要使用药物或出现需要医疗关注的症状。UtL 平均用时 6.5 分钟。在所有情况下,提取的 DNA 量均高于敏感、深度测序突变分析的下限。
我们的研究表明,使用新导管的 UtL 是一种安全、可靠且耐受良好的程序,不需要专门的培训。因此,UtL 满足了在潜在筛查环境中使用的所有先决条件。